Glasdegib: (Main) Keep away from coadministration of glasdegib with ciprofloxacin because of the potential for additive QT prolongation. If coadministration can’t be prevented, monitor patients for elevated threat of QT prolongation with elevated frequency of ECG monitoring. Glasdegib therapy could end in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. Uncommon circumstances of QT prolongation and torsade de pointes (TdP) have been reported with ciprofloxacin during postmarketing surveillance.
Insulin Degludec; Liraglutide: (Reasonable) Monitor blood glucose during concomitant incretin mimetic and quinolone use. Concomitant use could cause an elevated blood glucose-reducing effect with threat of hypoglycemia. (Reasonable) Monitor blood glucose during concomitant insulin and quinolone use. Concomitant use could cause an elevated blood glucose-decreasing impact with danger of hypoglycemia.
Barbiturates: (Moderate) Caffeine has been reported to increase the metabolism of barbiturates, and barbiturates increase caffeine elimination. Larger caffeine doses could also be wanted after barbiturate administration. (Minor) Chronic therapy with barbiturates can enhance the metabolism and lower the effectiveness of acetaminophen. Throughout acute overdoses, barbiturates can improve the formation of toxic acetaminophen metabolites.
Macitentan: buy dihydrocodeine (Major) Avoid coadministration of macitentan with ketoconazole as a consequence of the danger of elevated macitentan publicity and antagonistic results. Consider alternative treatment choices for pulmonary hypertension if therapy with ketoconazole is necessary. Macitentan is a CYP3A4 substrate and ketoconazole is a robust CYP3A4 inhibitor. Coadministration with ketoconazole elevated macitentan exposure by roughly 2-fold.